Seat­tle Ge­net­ics gets ready to launch its sec­ond ADC af­ter scor­ing blad­der can­cer OK with part­ner Astel­las

Seat­tle Ge­net­ics and Astel­las have scored a tru­ly ac­cel­er­at­ed ap­proval to de­ploy their armed an­ti­body in sec­ond-line urothe­lial can­cer, adding an­oth­er promi­nent drug to the list of 2019 OKs that the FDA has been dish­ing out well ahead of sched­ule.

Pad­cev is how en­for­tum­ab ve­dotin will be known on the mar­ket, where it will be a new op­tion for pa­tients with lo­cal­ly ad­vanced or metasta­t­ic urothe­lial can­cer — the most com­mon type of blad­der can­cer — fol­low­ing treat­ment with a PD-1/L1 in­hibitor and a plat­inum-con­tain­ing chemother­a­py. Des­ig­nat­ed a “break­through” ther­a­py by the FDA, it’s the first an­ti­body-drug con­ju­gate to be ap­proved for this ag­gres­sive dis­ease, the com­pa­nies not­ed, and it’s al­so the first prod­uct Seat­tle Ge­net­ics will be bring­ing in­to the mar­ket since Ad­cetris.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER